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Background: Various risk factors of aGVHD have already
been identiﬁed. However, organ-speciﬁc risk factors are yet
to be known, especially for hepatic aGVHD, which often in-
duces SCT-related mortality. Therefore, we conducted a
retrospective cohort study to determine whether pre-trans-
plant hepatic conditions are related to hepatic aGVHD after
allo-SCT by using a Japanese transplant registry database.
Patients and Methods: We included adult patients with
hematopoietic malignancies who underwent initial allo-SCT
between 2008 and 2012 in Japan. From the registry database,Figure 2we extracted the data on pre-transplant hepatic conditions,
such as hepatic dysfunction (elevation of AST/ALT and/or
T-Bil levels), hepatitis viral infection (HBs antigens and/or
HCV antibodies), and previous history of massive erythrocyte
transfusions ( 20 packs). Univariate analyses of the cumu-
lative incidence of hepatic aGVHD ( stage 1) were per-
formed using Gray’s methods, considering early death and
relapse as competitive risks. Fine and Gray’s proportional
hazards models were used to adjust for other confounders
such as donor sources and conditioning regimens.
Results: We evaluated 8,378 patients aged 16 to 80 years
(median, 49 years). Underlying diagnoses included AML
(46.3%), ALL (19.1%), MDS (12.3%), and NHL (10.9%). Disease
status at SCT was progressive in 48.6% of the patients, and
conditioning regimens were myeloablative in 30.2%. Donor
sources included UR-BM (46.1%), Rel-PB (21.0%), single CBT
(19.7%), and Rel-BM (13.2%). HLA was matched in 58.0%. As
aGVHD prophylaxis, tacrolimus were used in 61.2%. The HBs
antigen and HCV antibody were positive in 3.5% and 1.5%,
respectively. Pre-transplant hepatic dysfunction was
observed in 9.4%. The cumulative incidence of hepatic
aGVHD after SCT was 6.7% (95%CI, 6.2-7.3%; Figure 1), and
overall survival was poorer in the patients with hepatic
aGVHD complications (time-dependent covariant analyses;
hazard ratio [HR], 2.98; p < 0.01). The multivariate analyses
showed that hepatic dysfunction (HR, 1.85; p < 0.01) and.
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risk factors of hepatic aGVHD (Figure 2) and that hepatic
dysfunction due to HCV infection conferred an especially
higher risk (HR, 6.87; p < 0.01). These factors were speciﬁc
for hepatic aGVHD, and not signiﬁcant for skin or gut aGVHD.
HBs antigens (HR, 0.64; p ¼ 0.13) and massive erythrocyte
transfusions (HR, 1.08; p ¼ 0.44) were not signiﬁcant,
whereas SCT at progressive disease, Rel-PB or UR-BM, HLA
mismatch, and use of cyclosporine A as aGVHD prophylaxis
were signiﬁcant risk factors of hepatic aGVHD.
Discussion and Conclusion: This study suggests that
chronic inﬂammation and injury of liver before SCT can
induce aGVHD. Modiﬁcation of aGVHD prophylaxis and early
intervention may improve the prognosis of patients with
high-risk factors such as those indicated in this study.471
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Introduction: Patients undergoing hematopoietic stem cell
transplantation may experience a range of neurological
complications; moreover, etiologies for neurological com-
plications may be difﬁcult to differentiate but may occur
from the conditioning regimen, the interval of pancytopenia
lending to infection and bleeding, prophylactic drugs, or
from recurrence. Here we present a complex case of chronic
GVHD involving the Central Nervous System (CNS cGVHD).
Case Report: A 16-year old African American male under-
went mismatched unrelated allogeneic double UCBT for
biphenotypic leukemia. At day +25, the patient developed
rash to his palms and soles along with abdominal cramping,
voluminous diarrhea, nausea, vomiting, and fever. Biopsies of
the upper and lower GI tract were consistent with acute
GVHD. He was treated accordingly. Diarrhea only improved
with diet restriction.
His clinical coursewas further complicated by progressive
neurologic issues (anomic aphasia, confusion, agitation and
hallucinations). A new ill-deﬁned T2/FLAIR signal abnor-
mality was seen in the bilateral cerebral hemispheric white
matter (serum/CSF negative for infection or relapse). Brain
biopsy was considered but not performed during patient’s
course of altered mental status. Unfortunately he succumbed
to complications, the etiology of which was debated ad-
nauseam.
Examination of brain at autopsy revealed immune
mediated encephalitis, vasculitis, and CNS demyelination. A
diagnosis of “possible chronic CVHD of the CNS” was
rendered at the patient’s M&M.
Discussion: Neurological complications (regimen-related
toxicities, infections, cerebrovascular events and metabolic
disorders) pose a signiﬁcant source for morbidity and mor-
tality following allogeneic HSCT with the incidence varying
between 10 to 55% in reported studies. This case’s autopsyﬁndings revealed immune mediated encephalitis, multifocal
CNS demyelination, and vascular changes.
The neurological manifestations of CNS cGVHD are rare
and can affect both the peripheral and central nervous sys-
tem. However, CNS chronic GVHD remains controversial.
There have been at least 18 reported cases of presumed CNS
cGVHD since 1990 of which ﬁndings included demyelinating
disease, angiitis, vasculitis and immune-mediated encepha-
litis. The diagnostic criteria for chronic GVHD of the CNS
requires that all six of the following criteria for a deﬁnitive
diagnosis of CNS GVHD: (1) a-priori chronic GVHD affecting
other organs, (2) Neurological signs of CNS involvement, (3)
MRI abnormality, (4) Abnormal CSF studies, (5) Pathological
brain biopsy or post-mortem examination, and (6) Response
to therapy.
While the criteria allows for a very speciﬁc diagnosis of
CNS cGVHD, the criteria are too stringent. Herein, a modiﬁed
criteria stratiﬁed by pathologic examination of involved
neural tissue is proposed.472
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Background: Haplotype mismatches have been associated
with higher risk of GVHD in patients receiving 8/8 HLA
matched HCT. In addition a CIBMTR genomewide association
study identiﬁed SNP mismatches within the MHC region in
association with higher risk of GVHD. However, current
standard of care relies only onmatching at class I (A, B, C) and
class II (DRB1) loci. The gamma block (GB) is located in the
central MHC region between the genomic blocks that include
HLA-C/B and DRB1/DQB1 and is the only major genomic
block within the MHC not currently considered in HCT donor
selection. We tested the hypothesis that mismatches in the
GB increase the risk of GVHD.
Methods: We investigated 25 GB SNPs in 236 HCT recipient/
unrelated donor pairs transplanted at our center (2000-
2010). High resolution typing of HLA A, B, C, DRB1, DQB1,
DPB1 loci and for MHC class I related chain A (MICA) was
performed by sequence speciﬁc oligonucleotide probes and/
or sequencing. GB SNP typing was performed by sequence
speciﬁc primers. SNPs associated with severe acute GHVD
(grades III-IV) at P<0.20 were combined into a composite
variable. Multivariate analysis using Fine and Gray regression
was used to identify risk factors for severe acute GVHD with
adjustment for other signiﬁcant risk factors.
Results: The study included AML (n¼89), ALL (41), MDS (34),
NHL (28) and other diagnoses (44). Stem cell source was BM
